{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:16:33Z","timestamp":1787163393875,"version":"build-2736575974"},"reference-count":42,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T00:00:00Z","timestamp":1590451200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["eJHaem"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients receiving a variety of chemotherapy regimens often develop chemotherapy\u2010induced anemia (CIA), which contributes to poor outcomes including increased mortality. Prompt and effective treatment of CIA is essential to prevent fewer chemotherapy dose delays and reductions. Optimal therapy of CIA is controversial and involves the solitary and combined use of intravenous iron, red blood cell (RBC) transfusions, and erythropoietin stimulating agents (ESAs). Despite the baseline coagulopathies present in patients with malignancy, administration of both RBC transfusions and ESAs is associated with venous thromboembolism (VTE). It remains unknown whether the risk of VTE in patients with CIA is greater among patients who receive RBC transfusions or ESAs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective study analyzed 10,269 University of Pennsylvania Health System patients with malignancies of various type, stage, and histopathology who developed CIA between 2008 and 2017. Using multivariate Cox regression, we determined adjusted hazard ratios (and corresponding 95% confidence intervals) of VTE development after adjusting for RBC and ESA intervention (all during the 90 days following CIA diagnosis).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among the 10,269 patients with CIA, 2,642 (25.7%) developed a VTE within the 90\u2010day period. VTE risk following RBC transfusion (HR\u00a0=\u00a01.37, 95% CI 1.24\u20101.50,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u00a0.001) was more than twice as common as VTE risk following ESA administration (HR\u00a0=\u00a00.53,\u00a095% CI 0.40\u20100.69,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u00a0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>While both RBC transfusion and ESA are independently associated with VTE, our data suggest a greater risk of VTE development with RBC transfusion as compared with ESA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/jha2.18","type":"journal-article","created":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T11:03:51Z","timestamp":1590491031000},"page":"35-43","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A retrospective analysis of venous thromboembolism trends in chemotherapy\u2010induced anemia: Red blood cell transfusion versus erythrocyte stimulating agent administration"],"prefix":"10.1002","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3030-8738","authenticated-orcid":false,"given":"Emily J.","family":"Bryer","sequence":"first","affiliation":[{"name":"Pennsylvania Hospital University of Pennsylvania Health System  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Kallan","sequence":"additional","affiliation":[{"name":"Department of Biostatistics Epidemiology, and Informatics Perelman School of Medicine University of Pennsylvania  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting\u2010Shan","family":"Chiu","sequence":"additional","affiliation":[{"name":"Data Analytics Center Perelman School of Medicine University of Pennsylvania  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina M.","family":"Scheuba","sequence":"additional","affiliation":[{"name":"Pennsylvania Hospital University of Pennsylvania Health System  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Henry","sequence":"additional","affiliation":[{"name":"Pennsylvania Hospital University of Pennsylvania Health System  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,5,26]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-04-460121"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02374.x"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2005.10.015"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.21.2558-c"},{"key":"e_1_2_9_6_1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.nurpra.2015.10.015","article-title":"Understanding venous thromboembolism in patients with cancer","volume":"12","author":"Udon I.","year":"2016","journal-title":"J Nurse Practit"},{"key":"e_1_2_9_7_1","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1016\/S0049-3848(16)30105-0","article-title":"Risk of thrombosis in cancer and the role of supportive care (transfusion, catheters, and growth factors)","author":"Castaman G.","year":"2016","journal-title":"Thromb Res"},{"key":"e_1_2_9_8_1","first-page":"E4","article-title":"Drug\u2010related thrombosis in hematologic malignancies","volume":"1","author":"Nadir Y","year":"2004","journal-title":"Rev Clin Exp Hemtol"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13752"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.22262"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.1283"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.5669"},{"key":"e_1_2_9_13_1","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1182\/asheducation-2013.1.684","author":"Connolly GC","year":"2013","journal-title":"Hematology"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-270116"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr524"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-012-0784-y"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2017.08.003"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1053\/svms.2003.36632"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.168.21.2377"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-006-5206-4"},{"key":"e_1_2_9_21_1","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.3747\/co.2008.172","article-title":"Erythropoiesis\u2010stimulating agents: benefits and risks in supportive care of cancer","volume":"15","author":"Melosky BL","year":"2008","journal-title":"Curr Oncol"},{"key":"e_1_2_9_22_1","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/COC.0b013e31819cccaf","article-title":"Thromboembolic Events in Patients With Colorectal Cancer Receiving the Combination of Bevacizumab\u2010Based Chemotherapy and Erythropoietin Stimulating Agents","volume":"33","author":"Roddy JV","year":"2010","journal-title":"Am J Clin Oncol"},{"key":"e_1_2_9_23_1","first-page":"202","article-title":"Anemia in cancer patients\u2010expert group recommendations","volume":"13","author":"Radziwon P","year":"2017","journal-title":"Oncol Clin Pract"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.9-1-97"},{"key":"e_1_2_9_25_1","first-page":"288","article-title":"Erythropoietin or darbepoetin for patients with cancer","volume":"12","author":"Tonia T","year":"2012","journal-title":"Cochrane Lib"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25972"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.299.8.914"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djj189"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2011.07.047"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2009.02.003"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13019"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02142"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0096-1"},{"issue":"18","key":"e_1_2_9_34_1","article-title":"Older soft tissue sarcoma patients experience increased rates of venous thromboembolic events: a retrospective cohort study of SEER\u2010Medicare data","volume":"5","author":"Shantakumar S","year":"2015","journal-title":"Clin Sarcoma Res"},{"key":"e_1_2_9_35_1","doi-asserted-by":"crossref","first-page":"4726","DOI":"10.1182\/blood.V128.22.4726.4726","article-title":"Risk of venous thromboembolism in multiple myeloma: identification of risk factor","volume":"128","author":"Sanfillipo KM","year":"2016","journal-title":"Blood"},{"key":"e_1_2_9_36_1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1471-2369-12-67","article-title":"Association between high\u2010dose erythropoiesis\u2010stimulating agents, inflammatory biomarkers, andsoluble erythropoietin receptors","volume":"12","author":"Inrig JK","year":"2011","journal-title":"BMC Nephrology"},{"key":"e_1_2_9_37_1","unstructured":"NoxonV BennettC.Did the FDA black box warning have any effect on erythropoiesis\u2010stimulating agent use? Abstract 57: 2015 AVAHO Meeting. Available at:https:\/\/www.mdedge.com\/fedprac\/avaho\/article\/102926\/oncology\/did-fda-black-box-warning-have-any-effect-erythropoiesis"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14165"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14168"},{"issue":"3","key":"e_1_2_9_40_1","doi-asserted-by":"crossref","DOI":"10.1182\/hem.V15.3.8471","article-title":"The U.S. blood system under pressure","volume":"15","author":"Menitove J.","year":"2018","journal-title":"The Hematologist"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH12-11-0845"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.12948"},{"key":"e_1_2_9_43_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/bcj.2017.54","article-title":"Evaluation of coagulopathy before and during induction chemotherapy for acute lymphoblastic leukemia, including assessment of global clotting tests","volume":"7","author":"Burley K","year":"2017","journal-title":"Blood Cancer J"}],"container-title":["eJHaem"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjha2.18","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.18","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jha2.18","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T01:17:09Z","timestamp":1693876629000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jha2.18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,26]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["10.1002\/jha2.18"],"URL":"https:\/\/doi.org\/10.1002\/jha2.18","archive":["Portico"],"relation":{},"ISSN":["2688-6146","2688-6146"],"issn-type":[{"value":"2688-6146","type":"print"},{"value":"2688-6146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,26]]},"assertion":[{"value":"2020-03-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}